|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:activities
|
broad-spectrum
|
|
gptkbp:administered_by
|
oral tablet
intravenous injection
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:atccode
|
J01 MA14
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Vigamox
gptkb:Avelox
|
|
gptkbp:casnumber
|
218000-47-4
|
|
gptkbp:category
|
gptkb:C
not recommended
|
|
gptkbp:chemical_formula
|
C21 H24 FN3 O4
|
|
gptkbp:class
|
gptkb:fluoroquinolone
|
|
gptkbp:clinical_trial
|
Phase IV
Phase III
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
tendon rupture
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
gptkb:Ophthalmology
gptkb:cream
oral suspension
injectable solution
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
moxifloxacin
|
|
gptkbp:indication
|
skin infections
community-acquired pneumonia
acute bacterial sinusitis
intra-abdominal infections
|
|
gptkbp:interacts_with
|
gptkb:theophylline
gptkb:warfarin
gptkb:sucralfate
antacids
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:marketed_as
|
gptkb:Bayer_AG
gptkb:Bausch_+_Lomb
|
|
gptkbp:mechanism_of_action
|
inhibits bacterial DNA gyrase
inhibits topoisomerase IV
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
high bioavailability
well absorbed orally
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
hypersensitivity
photosensitivity
hepatotoxicity
QT prolongation
|
|
gptkbp:used_for
|
bacterial infections
|
|
gptkbp:bfsParent
|
gptkb:Vigamox
gptkb:Zymaxid
gptkb:Avelox
gptkb:fluoroquinolone
|
|
gptkbp:bfsLayer
|
7
|